Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 54,413 | 45,774 | 49,921 | 29,015 | 28,368 |
| Cost of Goods | 17,607 | 12,487 | 23,515 | 10,736 | 9,523 |
| Gross Profit | 36,806 | 33,287 | 26,406 | 18,279 | 18,845 |
| Operating Expenses | 93,760 | 80,484 | 171,332 | 96,499 | 77,210 |
| Operating Income | -56,347 | -46,710 | -144,411 | -77,484 | -57,842 |
| Interest Expense | 4,368 | 4,497 | 3,752 | 6,917 | 3,874 |
| Other Income | 2,549 | 2,736 | 2,211 | 408 | 281 |
| Pre-tax Income | -58,166 | -48,471 | -145,952 | -83,993 | -61,435 |
| Income Tax | N/A | N/A | N/A | 700 | N/A |
| Net Income Continuous | -58,166 | -48,471 | -145,952 | -84,693 | -61,435 |
| Net Income Discontinuous | -9,152 | -11,322 | N/A | N/A | N/A |
| Net Income | $-67,318 | $-59,793 | $-145,952 | $-84,693 | $-61,435 |
| EPS Basic Total Ops | -0.80 | -0.74 | -1.91 | -1.17 | -0.88 |
| EPS Basic Continuous Ops | -0.70 | -0.60 | -1.91 | -1.17 | -0.88 |
| EPS Basic Discontinuous Ops | -0.10 | -0.14 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.80 | -0.74 | -1.91 | -1.17 | -0.88 |
| EPS Diluted Continuous Ops | -0.70 | -0.60 | -1.91 | -1.17 | -0.88 |
| EPS Diluted Discontinuous Ops | -0.10 | -0.14 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -0.80 | -0.74 | -1.82 | N/A | N/A |
| EBITDA(a) | $-53,745 | $-41,325 | $-57,514 | $-68,547 | $-50,834 |